Articles tagged with Hiv Vaccines
New research finds increasing nanoparticle binding strength promotes stronger and more durable immune responses in mice. By fine-tuning molecular structures, researchers aim to create better vaccines for long-term HIV protection.
Researchers at Scripps Research Institute have made progress toward a long-sought vaccine capable of broad protection against HIV. The new approach, called germline-targeting sequential immunization, guides precursor B cells to produce broadly neutralizing antibodies that can recognize and block many different HIV strains.
Researchers at Scripps Research Institute developed an experimental vaccine that leads to broadly protective HIV antibodies in every rhesus macaque tested, a reliable outcome for vaccination alone.
A nationally representative survey of empaneled adults found that most Americans understand how STIs spread, but there are significant gaps in public knowledge about which infections can be prevented through vaccination. The survey also revealed strong awareness of common transmission pathways and some basic facts about STIs.
Researchers developed antibody–drug conjugates that combine CD4 mimic and neutralizing antibodies to target HIV entry, showing seven times better efficacy than existing approaches. The strategy aims to block HIV before it enters the host cell, offering a more targeted therapeutic profile and potentially reducing adverse effects.
Researchers developed a new device that can differentiate between active HIV infection and false positives caused by vaccines, with accuracy rates of 95% and 98%. This technology has the potential to accelerate vaccine development and improve diagnosis, addressing the limitations of existing diagnostics.
Experts Gregory Folkers and Anthony Fauci highlight promising therapeutic developments in antiretroviral treatments for HIV/AIDS. The authors emphasize the need for continued research to end the AIDS epidemic, citing recent advances as unfinished business.
A new AI system will help scientists rapidly pinpoint the most promising paths to an HIV vaccine by analyzing millions of potential vaccine designs and identifying the best candidates. The technology, funded by $1.1 million, aims to develop a long-lasting vaccine that adapts to mutations of the virus and can be delivered in a single dose.
A multidisciplinary team of scientists at Scripps Research has been awarded $6.9 million to identify more effective vaccines for treating HIV. By combining cutting-edge techniques and leveraging novel mouse models, the researchers aim to create a roadmap for building vaccines that provide lasting protection against HIV.
A successful HIV vaccine could be a major public health breakthrough, preventing 1.3 million new infections in 2024 and saving lives from the virus. The new childhood vaccine is based on the Env trimer protein complex and aims to elicit broadly neutralizing antibodies in young immune systems.
A new HIV antiretroviral compound, MK-8527, has demonstrated robust antiviral activity and pharmacokinetics in animal studies. The lead compound is a novel inhibitor of HIV reverse transcriptase translocation with potential for extended-duration dosing.
Researchers have developed a stable Env protein trimer, SOSIP.664, that can elicit broadly neutralizing antibodies against HIV. The breakthrough came after decades of work and multiple modifications to the protein, which is harder to engineer than its counterpart on SARS-CoV-2.
A new study shows that delivering a single injection of gene therapy at birth may offer years-long protection against HIV. The treatment uses an adeno-associated virus to deliver instructions to muscle cells, which produce broadly neutralizing antibodies capable of neutralizing multiple strains of HIV.
A two-part delivery strategy combining adjuvants improves antibody responses and follicular buildup of HIV protein in mouse model, offering new hope for effective HIV vaccine. The dual-adjuvant approach yields stronger and more potent immune responses than individual adjuvants alone.
Researchers have uncovered a key reason why HIV remains difficult to cure, revealing that subtle variations in the Rev-RRE axis influence viral replication and latency reactivation. Understanding this regulatory system could help develop strategies to flush out the dormant virus and eliminate it for good.
Researchers have discovered that high-affinity B cells can avoid degrading functional antibodies by 'banking' successful mutations and 'cloning' advantageous traits. This mechanism may lead to the development of more effective vaccines against pathogens like HIV, which constantly mutates and hides key targets.
Scientists discovered that repetitive HIV vaccinations can lead to the production of antibodies targeting immune complexes already bound to the virus. This chain reaction was observed in follow-up experiments on HIV-vaccinated animals and may impact vaccine design strategies. Understanding this response could lead to improved vaccines ...
A new hepatitis B vaccine, Heplisav-B, has been shown to be more effective than an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior vaccination. The study found that up to 99.4% of subjects received the new vaccine showed protective levels of antibodies.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
Researchers at Stanford University developed a nanoparticle platform to make vaccines more effective against various pathogens. The platform allows for the elicitation of different immune responses, enabling the identification of the most effective type of protection.
The PrEPVacc HIV vaccine trial found no significant reduction in HIV infections among participants. The study reported more infections in the vaccine arms compared to the placebo groups, but the results are inconclusive due to wide statistical confidence intervals.
Researchers conducted four preclinical studies indicating they're closer to an immunization regimen that could produce rare antibodies effective against a wide range of HIV strains. The findings build on a 2022 phase I clinical trial and represent a key step forward in an immunization strategy that could protect against the virus.
Researchers have successfully stimulated animals' immune systems to induce rare precursor B cells that can produce HIV broadly neutralizing antibodies. The findings are an encouraging step in developing a preventive HIV vaccine, targeting the challenging task of genetically diverse HIV.
A trial of an HIV vaccine candidate at Duke University Medical Center triggered broadly neutralizing antibodies in a small group of participants, providing proof that a vaccine can elicit these essential immune responses. The vaccine targetted the MPER region of the HIV outer envelope, which remains stable as the virus mutates.
Researchers at Ragon Institute of MGH, MIT and Harvard have developed a comprehensive platform for HIV vaccine research using the mRNA-LNP system. The platform has shown promising results in preclinically validating next-step boost immunogens and providing new insights into the basic biology of antibody responses.
A new approach developed by Duke Human Vaccine Institute guides the immune system through specific steps to make broadly neutralizing antibodies against HIV. The mutation-guided vaccine strategy has shown promise in triggering the immune system to produce desired antibodies, potentially applicable to vaccines targeting other diseases.
A new study aims to enhance and prolong vaccine effectiveness by delivering adjuvants to white blood cells using lipid nanoparticles. The research, led by WVU professor Sharan Bobbala, has the potential to provide broader protection against evolving viruses and multiple diseases.
Researchers at Duke University have discovered a critical structure on the HIV virus that plays a crucial role in its infection process. By understanding this structure's dynamics, scientists may be able to design broadly neutralizing antibodies for an AIDS vaccine.
Three different HIV antibodies independently protected monkeys from acquiring SHIV, providing statistically significant protection and dose-dependent effect. The findings support the HIV fusion peptide as a promising preventive vaccine target.
Researchers are exploring 'priming, shaping, and polishing' techniques to develop an HIV vaccine targeting rare immune cells that produce broad-neutralizing antibodies. The Amsterdam UMC-led project aims to create an effective vaccine for low- and middle-income countries with a €4.5m grant.
A new study suggests that stronger responses from immune cells called CD8+ T cells may be key to increasing HIV immunity. Future HIV vaccine candidates may benefit from additional doses or longer persistence in the body to further stimulate the immune system.
A new HIV prevention study, PrEPVacc, has stopped further vaccinations due to little or no chance of demonstrating vaccine efficacy in preventing HIV acquisition. The trial, testing two different combinations of HIV vaccines and a new oral PrEP drug formulation, aims to find out if either can prevent HIV infection.
A study of over 2,300 patients found that HIV-1 neutralizing antibody response decreases over time but highly potent broadly neutralizing antibodies remain detectable. This finding suggests a possible permanent vaccine response and is an important step toward developing an effective HIV-1 vaccine.
A Phase 1 trial of a preventive HIV vaccine candidate has begun enrollment in the US and South Africa. The vaccine, VIR-1388, aims to instruct immune cells to recognize and respond to HIV.
The African-led PrEPVacc trial has completed participant enrolment at all four sites in East and Southern Africa. The trial is testing two different ways to prevent HIV, including HIV vaccine regimens and a new form of oral pre-exposure prophylaxis (PrEP).
A Johns Hopkins Medicine-led team identified protein fragments that stimulate the immune system to recognize and attack HIV. The study's technique, called reductionist cell-free antigen processing, replicates the complex events in the human immune system, enabling the identification of immunodominant epitopes.
The study, published in Science Translational Medicine, shows robust T-cell responses in volunteers participating in a phase 1 clinical trial of a self-assembling nanoparticle HIV vaccine. The antigen used stimulates VRC01-class B cells, an immune response considered promising for boosting in further studies.
Research from Boston Medical Center found that pulmonary tuberculosis enhances HIV antibody responses and increases the prevalence of antibody-resistant strains. This study has significant implications for HIV vaccines and antibody-based therapies, highlighting the need for novel strategies to generate broad and potent antibodies.
A new HIV vaccine has shown improved ability to neutralize virus in preclinical tests, using nanoparticle display of multiple Env proteins. The vaccine design uses flexible sugar molecules called glycans to present self to the immune system.
A study has identified a severe form of mpox with a 15% mortality rate in people with advanced HIV disease and immunosuppression. The researchers recommend adding this form of mpox to the list of AIDS-defining conditions to guide management of immunocompromised individuals.
Researchers developed a vaccine platform that uses nanoscopic particles to deliver antigens, which can stimulate immune responses. The platform showed promise in early trials with mice, with improved survival rates against influenza and HIV.
A Phase 3 clinical trial testing an experimental HIV vaccine regimen found the treatment to be safe but ineffective in preventing HIV acquisition. The trial involved over 3,900 volunteers and concluded that the number of HIV infections were equivalent between the vaccine and placebo arms.
A modelling study in 90 low- and middle-income countries estimates that herpes simplex virus type 2 (HSV-2) infections drive significant healthcare cost savings and improved quality of life. The study suggests that widespread HSV-2 vaccination could prevent millions of quality of life years lost due to HSV-2 and HIV co-infections.
Researchers at Scripps Research, IAVI, Fred Hutch, and VRC publish study data in Science, revealing a stepwise approach to producing antibodies capable of targeting wide range of HIV variants. The Phase 1 trial shows favorable safety profile and induces targeted response in 97% of vaccinated individuals.
Researchers discovered that expressing Vpu in infected cells makes them more difficult for non-neutralizing antibodies to target, allowing the virus to evade the immune system. The study provides valuable insights into developing effective vaccines against HIV-1.
People living with HIV are at high risk of tuberculosis infection and disease, yet many questions remain unanswered about developing an effective TB vaccine. The NIH/DAIDS Cross-Network calls for their inclusion in clinical trials to prioritize access to safe and effective TB vaccines.
Researchers develop custom vaccines that induce broadly neutralizing antibodies to protect against HIV variants. The team uses a modified HIV spike protein to prime the immune system, paving the way for an effective HIV vaccine.
Researchers found that a 'slow delivery, escalating dose' vaccination strategy can prompt B cells to spend months mutating and evolving their antibodies, leading to more effective long-lasting vaccines. This breakthrough has implications for vaccines against pathogens like influenza, malaria, and SARS-CoV-2.
A newly defined biomarker called PT80 appears effective as a surrogate endpoint to predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1. PT80 predicts the 80% neutralizing antibody titer of a bnAb recipient's blood sample at a given time to a given virus.
Researchers have developed a new way to deliver vaccines through mucosal tissues in the nose, generating strong immune responses in mice and non-human primates. The technology bypasses traditional barriers to delivery by engineering antigens to bind onto albumin, allowing them to effectively target immune tissues.
The new tuberculosis vaccine candidate VPM1002 shows its safety and efficacy in a study of HIV-exposed and non-HIV-exposed newborns. The vaccine has fewer side effects compared to the existing BCG vaccine, and elicits a similar immune response.
A new study from Tel Aviv University developed a unique treatment for AIDS that may be developed into a vaccine or a one time treatment. The treatment involves engineering type B white blood cells to secrete anti-HIV antibodies in response to the virus.
A recent study published in JAMA Network Open found that people with HIV are at a higher risk of breakthrough COVID-19 infections after vaccination. The study analyzed data from nearly 114,000 fully vaccinated individuals and found that the HIV group had a 28% higher rate of breakthrough infections compared to the non-HIV group.
The HIV Vaccine Trials Network is launching a new registry to connect people interested in supporting HIV vaccine research with clinical trials in their communities. The 'Help End HIV' campaign aims to raise awareness about the urgent need for HIV clinical trial volunteers, particularly among young people.
A new grant will help Missouri parents make informed decisions about vaccinating their children against various diseases. The grant aims to provide factual, evidence-based information to address common concerns and promote public health outcomes.
New research suggests that ADCC responses and strain susceptibility influence HIV-1 mother-to-child transmission during breastfeeding. Enhancing ADCC through a vaccine may not be sufficient to prevent transmission due to chronically infected individuals' ADCC-resistant strains.
The authors advocate for integrated programs to diagnose, vaccinate, and manage HIV and COVID-19 patients, building on successful donor initiatives like PEPFAR and GFATM. This approach is crucial to address the intersecting pandemics and their detrimental effects on global health.
The National Institute of Allergy and Infectious Diseases is conducting a Phase 1 clinical trial evaluating three experimental HIV vaccines based on messenger RNA technology. The study aims to examine the safety and ability of the vaccines to induce an immune response in adults aged 18-55 years.
A new Phase 1 clinical trial has enrolled its first 12 participants, evaluating the safety and immune responses of three experimental HIV vaccines using mRNA technology. The study aims to understand how the immune system responds to these vaccines and gain insights into developing an HIV vaccine regimen.
Researchers at The Wistar Institute have developed a DNA-encoded immunogen that produces tier-2 neutralizing antibodies in mice, opening up new possibilities for HIV vaccine development. The study demonstrates the potential of using native-like trimer to generate broadly neutralizing antibody responses.